Haleon is voluntarily recalling four lots of Gas-X Extra Strength Softgels due to potential contamination during packaging, the company announced.

The recall affects specific 120-count and 72-count packages of Gas-X Extra Strength Softgels 125 mg distributed to consumers beginning April 13, 2026. According to the company, the affected products may have been contaminated with a diluted propylene glycol-based coolant due to a machine leak during packaging.

Haleon said consuming contaminated softgels could lead to adverse health effects, including nausea, vomiting, abdominal pain and diarrhea.

The company said it has not received any reports of adverse events linked to the recall.

Gas-X Extra Strength Softgels help break up gas bubbles in the digestive tract and relieve pressure, bloating, and discomfort. A green capsule and green-banded packaging identify the product.

The recall applies only to the following lots:

• Gas-X Extra Strength Softgels (120 count), UPC 300674350419, lot numbers TL8K, YH9X and YH9Y, all with expiration dates of November 30, 2028. These products were distributed between April 13 and May 5, 2026.
• Gas-X Extra Strength Softgels (72 count), UPC 300439005721, lot number X78N, with an expiration date of November 30, 2028. The product was distributed between May 5 and May 14, 2026.

No other lots of Gas-X Extra Strength or other Gas-X products, including Gas-X Ultra, Gas-X Maximum, and Gas-X Ultimate, are affected by the recall.

The recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Haleon said it is notifying distributors and customers by letter, email, and phone and is arranging for the return of recalled products.

Consumers who purchased Gas-X Extra Strength Softgels on or after April 13, 2026, are being urged to check the lot number on their product. Those with affected lots should stop using the product immediately and contact Haleon to arrange a return and reimbursement.

The company advised consumers who experienced health problems that may be related to the product to contact a physician or healthcare provider. Consumers may also report adverse events to Haleon or through the FDA’s MedWatch Adverse Event Reporting Program.

Haleon said the source of the contamination has been identified and repaired. The company added that corrective and preventive measures have been implemented to help prevent a recurrence.

“Consumer safety and product quality are our utmost priorities at Haleon,” the company said.